Seer, Inc. is a biotechnology company that develops proteomics technologies to enable unbiased, deep, and large-scale analysis of the proteome. The company's primary offering is the Proteograph Product Suite, a comprehensive solution comprising consumable assays, the SP200 automation instrument, and data analysis software. This platform utilizes proprietary engineered nanoparticle technology to provide peptide-level resolution across complex samples such as plasma, allowing researchers to detect protein isoforms, post-translational modifications, and variant peptides without reliance on predefined binding epitopes. Seer serves academic institutions, biopharmaceutical companies, biobanks, and clinical research organizations, supporting applications in biomarker discovery, disease biology, and AI-driven scientific discovery. The company’s commercial launch occurred in 2021. A notable spin-out from Seer is PrognomiQ, a multiomics diagnostic company that utilizes Proteograph data to develop blood-based tests for early lung cancer detection. The company’s technology is designed to bridge the gap between genetic variation and biological function by adding functional context to genomic information.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Diagnostics & Research Homepage seer.bio
Sector Healthcare IR page investor.seer.bio
Tags
proteomics, biomarker discovery, nanoparticle technology, precision medicine, biological research, assay development, data analysis software, clinical research, multiomics, protein analysis, Proteograph, Proteograph Product Suite, Proteograph ONE, SP200, PrognomiQ
Press page seer.bio/newsroom

Metrics

Valuation  
Market cap $ 124.467M
Market cap (USD) $ 124.467M
P/E -1.96
PEG —
P/BV 0.58
P/S 8.84
P/OCF -2.74
P/FCF -2.69
Dividend yield —
Turnover / mcap —
Returns  
ROE -25.1%
ROI -31.6%
ROIC -25.1%
Profit margin -444.0%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock Yes
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 32
Quality score -41.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 16.578M 14.17M 16.661M 15.493M 6.617M 656K
Net profit -73.6M -86.599M -86.277M -92.966M -71.169M -32.775M
Free cash flow -46.245M -49.693M -66.374M -71.045M -53.269M -25.362M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 1.83 2.31 1.94 5.8 22.81 56.14
Price performance 12m -0.21 0.19 -0.67 -0.75 -0.59 —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 0.00 2.5M 4.32M 4.83M — —
↳ YoY growth +72.9% +12.0%
Lease liabilities (USD) — 0.00 23.3M 29.9M 28.3M 26M 23.7M
Cash and deposits (USD) 17.8M 334M 233M 53.2M 32.5M 40.8M 47.3M
Right-of-use assets (USD) — 0.00 20.1M 27M 25.2M 22.8M 20.5M
Cash flow detail
Operating cash flow (USD) — -20.8M -46.3M -60.8M -59.1M -46.1M -44.4M
Purchases of property, plant and equipment (USD) — -4.53M -6.92M -10.3M -7.31M -3.58M -1.8M
Change in receivables (cash effect) (USD) — 0.00 -2.5M -1.82M 302,000 487,000 277,000
Change in inventories (cash effect) (USD) — -551,000 -3.59M -1.59M -1.95M -2.67M -2.9M
Change in payables (cash effect) (USD) — 912,000 1.6M -1.55M -987,000 3.36M 1.06M
Share buybacks (cash effect) (USD) — -13,000 -35,000 -20,000 -13,000 0.00 —
Income taxes paid (cash effect) (USD) — 0.00 -645,000 -232,000 0.00 -154,000 -182,000
Share-based compensation (USD) — 7.35M 25.9M 33.7M 34.4M 28.2M 15.4M
Operating cash flow before change in receivables (USD) — -20.8M -43.9M -59M -59.4M -46.6M -44.7M
Free cash flow (OCF - PPE - intangibles) (USD) — -25.4M -53.3M -71M -66.4M -49.7M -46.2M
Income detail
Research and development expense (USD) — 18.9M 29.1M 45.8M 53M 50.6M 43.9M
↳ 5y CAGR +18.3%
Total comprehensive income (USD) — -32.7M -71.8M -93.7M -85.2M -86.3M -73.3M
Comprehensive income to owners (USD) — -32.7M -71.8M -93.7M -85.2M -86.3M -73.3M
Reported May 11, 2021 Mar 1, 2022 Mar 1, 2022 Mar 6, 2023 Mar 3, 2025 Mar 3, 2025 Mar 2, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

REDWOOD CITY, Calif. – November 10, 2026 – Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced financial results for the quarter ended September 30, 2026.

Seer reported third-quarter revenue of $4.0 million, compared with $3.1 million in the second quarter of 2026, and ended the quarter with approximately $198.1 million in cash, cash equivalents and investments. Seer also updated its full-year 2026 revenue guidance to a range of $13.5 million to $14.5 million.

“This quarter, our customers continued to demonstrate what Proteograph makes possible, from new discoveries in population-scale research to emerging applications in AI, while established customers returned to purchase consumables and new pharmaceutical customers adopted the platform,” said Omid Farokhzad, Chair and Chief Executive Officer. “Proteograph fundamentally expands the biology researchers can see with mass spectrometry. Our focus is to translate that differentiated value into sustained revenue growth by expanding sample volume within customer accounts and building relationships that support repeat use.

November 5, 2026

PDF Version

ITC investigative staff recommends full exclusion and cease-and-desist orders sought by Seer

REDWOOD CITY, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a pioneer and trusted partner for deep, unbiased proteomic insights, today announced a significant victory in its patent enforcement action against Nanomics Biotechnology Co., Ltd. before the U.S. International Trade Commission (ITC). In May, Seer asked the ITC to investigate Nanomics’ Proteonano line of products, including the Plasma Proteome Enrichment Kit and the HT Assay. Seer took this action to ensure that scientists receive the highest quality, most reproducible results in their proteomics research. Following institution of the investigation and the exchange of initial discovery responses, Nanomics notified the ITC in September that it would no longer defend itself or participate in the investigation.

Under ITC rules, Nanomics’ default means that the allegations in Seer's complaint are presumed true with respect to Nanomics’ products, allowing the Commission to shift its attention to the issue of the exclusion and cease and desist orders requested by Seer, without further litigation of the underlying allegations. On October 30, responsive to the Commission’s request for comment, the ITC’s Office of Unfair Import Investigations (OUII) recommended granting the full remedies requested by Seer, including orders to block imports of infringing Proteonano products and prohibit Nanomics from attempting, directly or indirectly, to commercialize such imported products in the United States. There were no third-party submissions opposing the orders requested by Seer. The Commission is expected to reach a final determination by year’s end.

"Seer pioneered the design and development of engineered nanoparticles for protein enrichment and built the foundational intellectual property that protects this technology," said Omid Farokhzad, Chair and Chief Executive Officer of Seer. “Our customers commit precious samples, time and resources to scientific discovery, and we will vigorously defend our intellectual property against infringement to protect the innovation they rely on. We are pleased to see the ITC action advancing toward the exclusion of Nanomics' copycat products and the protection of scientific research.”

The Brigham and Women's Hospital (BWH) is a co-complainant in the ITC proceeding. Seer and BWH continue to pursue a related patent infringement lawsuit against Nanomics in U.S. federal district court.

These developments follow additional favorable intellectual property decisions for Seer in 2026, including a March ruling by the U.S. Patent Trial and Appeal Board upholding key claims of a patent protecting Seer's nanoparticle protein enrichment technology and a June decision by the European Patent Office maintaining a patent covering particle-based enrichment for proteomics.

About Seer, Inc. Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with a scale, speed, precision and reproducibility previously unattainable. Seer’s Proteograph® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.

October 29, 2026

PDF Version

REDWOOD CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the Special Committee of Seer’s Board of Directors (the “Special Committee”) has concluded its review process and decided to reject the recent acquisition proposals made to Seer.

“Over the last three months, we have worked closely with our legal and financial advisors to carefully evaluate the unsolicited acquisition proposals that Seer has received, as well as other strategic alternatives, including through a careful assessment of possible interest from alternative potential transaction counterparties,” said independent directors Meeta Gulyani and Nicolas Roelofs, Ph.D., the members of the Special Committee. “We approached this process with no options off the table. Our work was thorough, deliberative and focused on shareholder value. Following this review, we have concluded that a sale of Seer at this time would undervalue the company and our future prospects. We are confident that Seer is well positioned to meet the growing demand for deep, large-scale, unbiased proteomics in the era of AI-biology and we look forward to capturing the opportunities ahead.”

As previously disclosed, on July 28, 2026, Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”) submitted an unsolicited, non-binding proposal to acquire all outstanding shares of Seer’s Class A common stock for $2.55 per share in cash plus a contingent value right. On July 29, 2026, Omid Farokhzad, M.D., Seer’s Chair and Chief Executive Officer, submitted an unsolicited, non-binding proposal to acquire all outstanding shares of Seer’s Class A common stock for $2.45 per share in cash plus two separate contingent value rights.

After careful consideration, the Special Committee determined that both of the unsolicited acquisition proposals fail to reflect Seer’s intrinsic value. As such, the Special Committee has unanimously rejected both unsolicited acquisition proposals.

About Seer, Inc. Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with a scale, speed, precision and reproducibility previously unattainable. Seer’s Proteograph® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.

Prompts

Seer, Inc. (ticker SEER), listed in United States.

Company History

Date Change Detail
Sep 25, 2020 Renamed Seer Biosciences, Inc. → SEER, INC.

ETFs Holding Seer, Inc.

ETF Weight in ETF Shares Market value As of
DFSU 0.00% 11,353 $ 18.051K Nov 12, 2026
DXUV 0.00% 6,516 $ 10.36K Nov 12, 2026
DFAS 0.00% 15,590 $ 24.788K Nov 12, 2026
DCOR 0.00% 5,033 $ 8,002.47 Nov 12, 2026
AVUS 0.00% 6,973 $ 10.32K Nov 16, 2026
AVSC 0.00% 61,532 $ 91.067K Nov 16, 2026